Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now early-phase tilt

Diabetic Retinopathy: early-phase trial registry

15 of 58 indexed Diabetic Retinopathy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #244 of 28,707 conditions by registered trial count.

58 US clinical trials · 15 currently recruiting · #244 of 28,707 conditions by registered trial count

Diabetic Retinopathy: 58 US clinical trials tracked, 15 recruiting.

Diabetic Retinopathy is the subject of 58 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 4 of these trials.

Enrollment posture brief

Registry condition diabetic-retinopathy

OPEN 15 | RECR 26% | LATE 8 | EARLY 21 | RANK #244 | SPON 4

Nearest open-share peer: Coronary Artery Disease (26% recruiting · 220 trials)

Recurrent Acute Myeloid Leuk51.7%Anesthesia43.1%Exercise41.4%Non-alcoholic Fatty Liver Di32.8%Diabetic Retinopathy (this)26%
Open-enrollment share among volume-matched conditions near Diabetic Retinopathy

Diabetic Retinopathy lists 15 open slots (26% of 58 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetic Retinopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetic Retinopathy is recruiting below its size-band peers.

    15 of 58 indexed trials (25.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetic Retinopathy trials is spread across many organizations.

    National Eye Institute (NEI) accounts for 4 of 58 trials (6.9%). 45 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetic Retinopathy enrolment sits around 178 participants.

    Median target enrolment is 178 among the 58 trials that report a genuine target (sentinel values excluded). 20 of those (34.5%) plan for fewer than 100 participants.

  4. Diabetic Retinopathy splits between interventional and observational designs.

    39 interventional and 19 observational studies make up this index (67.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 18Phase 213Phase 37Phase 41

Open and recent trials

58 total, page 1 of 2

RECRUITING NA 60,200 participants

Village-Integrated Eye Worker Trial II

University of California, San Francisco

NCT03752840

RECRUITING NA 5,000 participants

Clinical Applications of Advanced Ophthalmic Imaging

University of Miami

NCT03135327

RECRUITING NA 1,526 participants

Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities

University of Wisconsin, Madison

NCT06257082

RECRUITING NA 1,050 participants

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Johns Hopkins University

NCT04505618

RECRUITING 922 participants

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

iHealthScreen

NCT07151001

RECRUITING 650 participants

National Eye Institute Biorepository for Retinal Diseases

National Eye Institute (NEI)

NCT01496625

RECRUITING Phase 3 560 participants

Fenofibrate for Prevention of DR Worsening

Jaeb Center for Health Research

NCT04661358

RECRUITING 262 participants

Intraoperative OCT Guidance of Intraocular Surgery II

Duke University

NCT03713268

RECRUITING 192 participants

Biomarker of Diabetic Retinopathy

Indiana University

NCT05079399

RECRUITING Phase 2 178 participants

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Boehringer Ingelheim

NCT06321302

RECRUITING 104 participants

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

University of Alabama at Birmingham

NCT03403686

RECRUITING Phase 2 100 participants

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

Vantage Biosciences

NCT06770933

RECRUITING Phase 2 42 participants

Sleep, Diabetic Retinopathy and Melatonin

University of Illinois at Chicago

NCT04547439

RECRUITING 20 participants

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

University of Alabama at Birmingham

NCT03403699

RECRUITING Early Phase 1 10 participants

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

MediBeacon

NCT04008121

ACTIVE NOT RECRUITING NA 12,840 participants

Implementation of Teleophthalmology in Urban Health Systems Study

University of Wisconsin, Madison

NCT05773495

ACTIVE NOT RECRUITING NA 749 participants

Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)

Columbia University

NCT04271709

ACTIVE NOT RECRUITING 626 participants

Camera Qualification Study

Digital Diagnostics

NCT05808699

ACTIVE NOT RECRUITING 300 participants

Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images

Charles Drew University of Medicine and Science

NCT03694145

ACTIVE NOT RECRUITING 290 participants

WF and PR OCTA in Diabetic Retinopathy

Oregon Health and Science University

NCT03922932

ACTIVE NOT RECRUITING Phase 3 255 participants

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Kodiak Sciences

NCT06270836

ACTIVE NOT RECRUITING Phase 3 174 participants

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

Hoffmann-La Roche

NCT04503551

ACTIVE NOT RECRUITING 165 participants

OCT Biomarkers for Diabetic Retinopathy

Oregon Health and Science University

NCT02330042

ACTIVE NOT RECRUITING Phase 1 164 participants

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

Stephen J. Kim, MD

NCT04505566

ACTIVE NOT RECRUITING 78 participants

Vascular Reparative Mechanism in Diabetes

University of Alabama at Birmingham

NCT02119689

ACTIVE NOT RECRUITING Phase 2 72 participants

4D-150 in Patients With Diabetic Macular Edema

4D Molecular Therapeutics

NCT05930561

ACTIVE NOT RECRUITING Phase 2 24 participants

A Study of PER-001 in Participants With Diabetic Retinopathy

Perfuse Therapeutics

NCT06003751

ACTIVE NOT RECRUITING 22 participants

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Adverum Biotechnologies

NCT05607810

ACTIVE NOT RECRUITING Phase 1 15 participants

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

University of California, Davis

NCT01736059

COMPLETED NA 2,000 participants

Study to Evaluate the Effectiveness of a Program Developed to Improve Eye Care for Veterans With Diabetes

US Department of Veterans Affairs

NCT00119535

COMPLETED 942 participants

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

Eyenuk

NCT03112005

COMPLETED Phase 3 750 participants

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

Bausch & Lomb Incorporated

NCT00198510

COMPLETED Phase 3 731 participants

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Chromaderm

NCT00090519

COMPLETED 609 participants

Genetics and Markers of Degenerative and Inflammatory Eye Diseases

National Eye Institute (NEI)

NCT00647439

COMPLETED NA 567 participants

The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy

Legacy Health System

NCT01364129

COMPLETED 500 participants

Pediatric Type 1 Diabetes and Retinopathy

University of Florida

NCT02691312

COMPLETED NA 468 participants

RETeval Study for Diabetic Retinopathy

Inoveon Corporation

NCT01950663

COMPLETED Phase 3 399 participants

Anti-VEGF Treatment for Prevention of PDR/DME

Jaeb Center for Health Research

NCT02634333

COMPLETED 331 participants

Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)

VisionQuest Biomedical

NCT03069729

COMPLETED Phase 3 312 participants

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Novartis

NCT00130845

COMPLETED Phase 2 258 participants

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

Quark Pharmaceuticals

NCT01445899

COMPLETED Phase 2 230 participants

Levodopa for Diabetic Retinopathy

Emory University

NCT07444892

COMPLETED Phase 2 139 participants

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Hoffmann-La Roche

NCT04265261

COMPLETED Phase 2 135 participants

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Oxurion

NCT04527107

COMPLETED Phase 2 121 participants

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

Jaeb Center for Health Research

NCT00336323

COMPLETED Phase 1 120 participants

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

National Eye Institute (NEI)

NCT00101764

COMPLETED 70 participants

Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart

Julia Haller

NCT01622816

COMPLETED 51 participants

Comparing 3 Imaging Systems

University of Wisconsin, Madison

NCT05022615

COMPLETED Phase 2 49 participants

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

Rocky Mountain Retina Consultants

NCT00387582

COMPLETED Phase 1 44 participants

A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers

TargeGen

NCT00414999

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 13
Phase 3 7
Phase 4 1

Named interventions

Most-linked intervention names on Diabetic Retinopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
THR-149 dose level 3 Drug
2 trials
THR-149 dose level 2 Drug
2 trials
THR-149 dose level 1 Drug
2 trials
Placebo Other
2 trials
Peribulbar Triamcinolone Acetonide Drug
1 trials
RG7774 Drug
1 trials
Deferred aflibercept Drug
1 trials

US sites by state

Facility locations filed on Diabetic Retinopathy trials. A trial with sites in several states counts in each.

California 21 trials
Florida 18 trials
Maryland 13 trials
Georgia 10 trials
Arizona 10 trials
Illinois 9 trials
Texas 7 trials
Connecticut 7 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetic Retinopathy page

58 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Retinopathy condition card totals 58 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.